Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the ...

BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $26 from $30 and keeps a Buy rating on the shares. While ...

China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment ...

In a move designed to advance its pipeline and its “innovative medicines business,” Chinese biotech Hutchmed will ...

Limited, a biopharmaceutical company under Hong Kong-listed conglomerate CK Hutchison Holdings, has agreed to sell its 45% ...

HUTCHMED (China) has agreed to sell a 45% equity interest in the non-core, non-consolidated joint venture (JV) Shanghai ...

Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

Hutchmed, a biopharmaceutical company controlled by Hong Kong’s wealthiest person Li Ka-shing, is divesting a 45% stake in a cardiovascular joint venture for about $608 million as it looks to ...

Hutchmed sells its 45% stake in SHPL for $608 million, aligning with its focus on oncology and immunology. Proceeds will fund ...

Biopharmaceutical firm Hutchmed China Ltd., backed by Hong Kong billionaire Li Ka-shing, saw its shares rally on Thursday ...